Share on Facebook Share on Twitter Email
Answers.com

Progressive multifocal leukoencephalopathy

 
Medical Encyclopedia: Progressive Multifocal Leukoencephalopathy
More about Progressive Multifocal Leukoencephalopathy:
Causes and symptoms
Diagnosis
Treatment
Prognosis
Resources

Definition

Progressive multifocal leukoencephalopathy (PML) is a rapidly progressive neuromuscular disease caused by opportunistic infection of brain cells (oligodendrocytes and astrocytes) by the JC virus (JCV).

Description

PML is an opportunistic infection associated with AIDS and certain cancers. It occurs in people with inadequate immune response and carries a poor prognosis. The incidence of PML, once quite rare, is rising as the numbers of people living with persistently compromised immune systems rises. An estimated 2–7% of people with HIV disease will develop PML. The infection also occurs among people undergoing long-term chemotherapy for cancer. PML is not considered a contagious disease. According to the Centers for Disease Control definition of AIDS, PML in the presence of HIV infection is sufficient to form a diagnosis of AIDS.

— Jill S. Lasker



Search unanswered questions...
Enter a question here...
Search: All sources Community Q&A Reference topics
Neurological Disorder:

Progressive multifocal leukoencephalopathy

Top

Definition

Progressive multifocal leukoencephalopathy is a rare, fatal disease of the white matter of the brain that almost solely strikes individuals who already have weakened immune systems.

Description

In progressive multifocal leukoencephalopathy, myelin (the substance that wraps around nerve fibers, providing insulation and speeding nerve transmission) is progressively destroyed. Although the disease is caused by a very prevalent virus (called JC virus), it only develops in individuals who are immunocompromised (have weakened immune systems).

Multiple areas of the brain are affected by the demyelination associated with progressive multifocal leukoencephalopathy. Additionally, other abnormalities and bizarre cells take up residence within the brain, causing destruction of normal brain tissue and impairing normal function.

Demographics

The causative virus in progressive multifocal leukoencephalopathy, JC virus, is extremely common. It is thought to be present in upwards of 85% of all children before the age of nine, and probably is present in an even greater percentage of adults. However, the JC virus does not actually cause any symptoms or disease, except in individuals who have severely compromised immune systems. About 62.2% of all progressive multifocal leukoencephalopathy cases occur in individuals with lymphatic cancers (lymphoproliferative disease, such as Hodgkin's disease and other lymphomas); 6.5% occur in individuals with cancer of bone marrow cells (myeloproliferative disease or leukemias); 2.2% occur in individuals with carcinomatous disease (cancers that affect the lining of tissues or organs of the body); and 10% occur in individuals with any of a number of acquired immunodeficiency states (such as systemic lupus erthematosus, sarcoidosis, and organ transplant survivors). Among patients with Acquired Immunodeficiency Syndrome (AIDS), about 10% of patients develop progressive multifocal leukoencephalopathy. Only 5.6% of all cases of progressive multifocal leukoencephalopathy occur in individuals with no other underlying source of immunocompromise.

Causes and symptoms

Although much is left to be defined about the mechanism whereby progressive multifocal leukoencephalopathy affects an individual, researchers believe that the JC virus resides in the kidneys of most individuals. In normal, nonimmunocompromised individuals, the virus stays within the kidneys, doing no harm. In immunocompromised individuals, the virus is reactivated, travels through the circulatory system to the brain, and selectively destroys myelinated nerve cells.

Patients with progressive multifocal leukoencephalopathy experience a range of symptoms that grow gradually worse over time, including headache and difficulties with speech, thinking, walking, weakness, vision problems (even blindness), memory problems, confusion, slowness of movement, paralysis of half of the body, and seizures. Eventually, patients lapse into a coma and die, usually within just months of the onset of their initial symptoms.

Diagnosis

Diagnosis is usually suggested by a patient's characteristic symptoms of progressive multifocal leukoencephalopathy, in combination with evidence of white matter destruction visualized on CT or MRI scanning of the brain. Specialized tests on cerebrospinal fluid (called polymerase chain reactions) may demonstrate the presence of JC virus DNA. However, only brain biopsy can result in an absolutely definitive diagnosis.

Treatment team

Patients with progressive multifocal leukoencephalopathy are usually seen by neurologists, as well as by hematologist/oncologists for patients with lymphoma or leukemia, infectious disease specialists for patients with AIDS, and a rheumatologist for individuals with specific autoimmune disease.

Treatment

There are no treatments available to cure progressive multifocal leukoencephalopathy. Some degree of slowing of the relentless progression of the disease has been noted in certain patients treated with the AIDS drug AZT.

Prognosis

Progressive multifocal leukoencephalopathy is uniformly fatal, usually within one to four months of the initial symptoms. A few patients have had brief remissions in the disease progression, and have lived for several years beyond diagnosis.

Resources

BOOKS

Berger, Joseph R., and Avindra Nath. "Progressive Multifocal Leukoencephalopathy." In Cecil Textbook of InternalMedicine, edited by Lee Goldman, et al. Philadelphia: W. B. Saunders Company, 2000.

Roos, Karen L. "Viral Infections." In Textbook of Clinical Neurology, edited by Christopher G. Goetz. Philadelphia: W. B. Saunders Company, 2003.

Tyler, Kenneth L. "Viral Meningitis and Encephalitis." In Harrison's Principles of Internal Medicine, edited by Eugene Braunwald, et al. NY: McGraw-Hill Professional, 2001.

PERIODICALS

Pruitt, A. A. "Nervous System Infections in Patients with Cancer." Neurol Clin 21, no. 1 (February 1, 2003): 193–219

WEBSITES

National Institute of Neurological Disorders and Stroke (NINDS). NINDS Progressive Multifocal Leukoencephalopathy Information Page. May 29, 2002. (June 4, 2004). http://www.ninds.nih.gov/health_and_medical/disorders/pml_doc.htm.


Rosalyn Carson-DeWitt, MD


Wikipedia: Progressive multifocal leukoencephalopathy
Top
Progressive multifocal leukoencephalopathy
Classification and external resources
ICD-10 A81.2
ICD-9 046.3
DiseasesDB 10718
MedlinePlus 000674
eMedicine radio/573
MeSH D007968

Progressive multifocal leukoencephalopathy (PML), also known as progressive multifocal leukoencephalitis, is a rare and usually fatal viral disease that is characterized by progressive damage (-pathy) or inflammation of the white matter (leuko-) of the brain (-encephalo-) at multiple locations (multifocal). It occurs almost exclusively in people with severe immune deficiency, e.g. transplant patients on immunosuppressive medications, patients receiving certain kinds of chemotherapy, patients receiving Natalizumab (Tysabri)[1] for multiple sclerosis, psoriasis patients on long-term Efalizumab (Raptiva)[2] or AIDS patients.

It is caused by the JC virus.

Contents

Cause

The cause of PML is a type of polyomavirus called the JC virus (JCV), after the initials of the patient from whose tissue the virus was first successfully cultured. The virus is widespread, with 86% of the general population presenting antibodies, but it usually remains latent, causing disease only when the immune system has been severely weakened.

Prior to the advent of effective antiretroviral therapy, as many as 5 percent of people with AIDS eventually developed PML.[3] It is unclear why PML occurs more frequently in AIDS than in other immunosuppressive conditions; some research suggests that the effects of HIV on brain tissue, or on JCV itself, make JCV more likely to become active in the brain and increase its damaging inflammatory effects.[4]

Contributing causes

There are case reports of PML being caused by pharmacological agents, although there is some speculation this could be due in part to the existing impaired immune response or 'drug combination therapies' rather than individual drugs. These include efalizumab, rituximab,[5] infliximab,[6] natalizumab,[7] chemotherapy,[8] corticosteroids,[9] and various transplant drugs such as tacrolimus.[10]

Disease process

PML is a demyelinating disease, in which the myelin sheath covering the axons of nerve cells is gradually destroyed, impairing the transmission of nerve impulses. It affects the white matter, which is mostly composed of axons from the outermost parts of the brain (cortex). Symptoms include weakness or paralysis, vision loss, impaired speech, and cognitive deterioration. PML destroys oligodendrocytes and produces intranuclear inclusions. PML is similar to another demyelinating disease, multiple sclerosis, but since it destroys the cells that produce myelin (unlike MS, in which myelin itself is attacked but can be replaced), it progresses much more quickly. The median survival of patients with PML as a complication of AIDS is 6 months. In 10% of patients, survival exceeds 12 months. The longest reported survival is 11 years and 9 months from the onset of illness.

Diagnosis

PML is diagnosed by testing for JC virus DNA in cerebrospinal fluid or in a brain biopsy specimen. Characteristic evidence of the damage caused by PML in the brain can also be detected on MRI images.

Treatment

There is no known cure. In some cases, the disease slows or stops if the patient's immune system improves; some AIDS patients with PML have been able to survive for several years, with the advent of highly active antiretroviral therapy (HAART).

AIDS patients who start HAART after being diagnosed with PML tend to have a slightly longer survival time than patients who were already on HAART and then develop PML.[11] A rare complication of effective HAART is immune reconstitution inflammatory syndrome (IRIS), in which increased immune system activity actually increases the damage caused by the infection; though IRIS is often manageable with other types of drugs, it is extremely dangerous if it occurs in PML.[12]

Other antiviral agents that have been studied as possible treatments for PML include cidofovir[13] and interleukin-2, but this research is still preliminary.

Cytarabine (also known as ARA-C), a chemotherapy drug used to treat certain cancers, has been prescribed on an experimental basis for a small number of non-AIDS PML patients. It is reported to have stabilized the neurological condition of a minority of these patients.[14] One patient regained some cognitive function lost as a result of PML.[15]

See also

References

  1. ^ http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9OTIyMXxDaGlsZElEPS0xfFR5cGU9Mw==&t=1
  2. ^ http://www.medpagetoday.com/MeetingCoverage/SDEF/12849
  3. ^ "National Institutes of Health, Progressive Multifocal Leukoencephalopathy Information Page". http://www.ninds.nih.gov/disorders/pml/pml.htm. 
  4. ^ Berger JR (2003). "Progressive multifocal leukoencephalopathy in acquired immunodeficiency syndrome: explaining the high incidence and disproportionate frequency of the illness relative to other immunosuppressive conditions". J. Neurovirol. 9 Suppl 1: 38–41. doi:10.1080/713831410. PMID 12709870. http://www.informaworld.com/openurl?genre=article&doi=10.1080/13550280390195261&magic=pubmed. 
  5. ^ "Off-Label Use of Rituxan Linked to Fatal Leukoencephalopathy". http://www.medscape.com/viewarticle/549598. 
  6. ^ Lavagna A, Bergallo M, Daperno M, et al. (2007). "Infliximab and the risk of latent viruses reactivation in active Crohn's disease". Inflamm. Bowel Dis. 13 (7): 896–902. doi:10.1002/ibd.20131. PMID 17345605. 
  7. ^ "Potential risks of powerful MS drug are weighed - health - 2 March 2006 - New Scientist". http://www.newscientist.com/channel/health/dn8796.html. Retrieved 2008-01-28. 
  8. ^ Connolly RM, Doherty CP, Beddy P, O'Byrne K (2007). "Chemotherapy induced reversible posterior leukoencephalopathy syndrome". Lung Cancer 56 (3): 459–63. doi:10.1016/j.lungcan.2007.01.012. PMID 17316891. http://linkinghub.elsevier.com/retrieve/pii/S0169-5002(07)00050-5. 
  9. ^ Viallard JF, Lazaro E, Ellie E, et al. (2007). "Improvement of progressive multifocal leukoencephalopathy after cidofovir therapy in a patient with a destructive polyarthritis". Infection 35 (1): 33–6. doi:10.1007/s15010-006-5103-y. PMID 17297588. 
  10. ^ Junna MR, Rabinstein AA (2007). "Tacrolimus induced leukoencephalopathy presenting with status epilepticus and prolonged coma". J. Neurol. Neurosurg. Psychiatr. 78 (12): 1410–1. doi:10.1136/jnnp.2007.121806. PMID 18024699. http://jnnp.bmj.com/cgi/pmidlookup?view=long&pmid=18024699. 
  11. ^ Wyen, C., Hoffmann, C., Schmeisser, N., Wohrmann, A., Qurishi, N., Rockstroh, J., Esser, S., Rieke, A., Ross, B., Lorenzen, T., Schmitz, K., Stenzel, W., Salzberger, B. and Fatkenheuer, G. (2004) Progressive multifocal leukencephalopathy in patients on highly active antiretroviral therapy: survival and risk factors of death. Journal of Acquired Immune Deficiency Syndrome 37, 1263-1268. PMID 15385733
  12. ^ Vendrely A, Bienvenu B, Gasnault J, Thiebault JB, Salmon D, Gray F (April 2005). "Fulminant inflammatory leukoencephalopathy associated with HAART-induced immune restoration in AIDS-related progressive multifocal leukoencephalopathy". Acta Neuropathol. 109 (4): 449–55. doi:10.1007/s00401-005-0983-y. PMID 15739098. 
  13. ^ Segarra-Newnham M, Vodolo KM (June 2001). "Use of cidofovir in progressive multifocal leukoencephalopathy". Ann Pharmacother 35 (6): 741–4. doi:10.1345/aph.10338. PMID 11408993. http://www.theannals.com/cgi/pmidlookup?view=long&pmid=11408993. 
  14. ^ Aksamit AJ (August 2001). "Treatment of non-AIDS progressive multifocal leukoencephalopathy with cytosine arabinoside". J. Neurovirol. 7 (4): 386–90. doi:10.1080/13550280152537292. PMID 11517422. 
  15. ^ Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D (July 2005). "Progressive multifocal leukoencephalopathy in a patient treated with natalizumab". N. Engl. J. Med. 353 (4): 375–81. doi:10.1056/NEJMoa051847. PMID 15947078. 

External links


 
 

 

Copyrights:

Medical Encyclopedia. © 2006 through a partnership of Answers Corporation. All rights reserved.  Read more
Neurological Disorder. Gale Encyclopedia of Neurological Disorders. Copyright © 2005 by The Gale Group, Inc. All rights reserved.  Read more
Wikipedia. This article is licensed under the Creative Commons Attribution/Share-Alike License. It uses material from the Wikipedia article "Progressive multifocal leukoencephalopathy" Read more